0001140361-21-006728.txt : 20210301 0001140361-21-006728.hdr.sgml : 20210301 20210301190341 ACCESSION NUMBER: 0001140361-21-006728 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210225 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coiante Scott M CENTRAL INDEX KEY: 0001608536 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 21700422 MAIL ADDRESS: STREET 1: 101 POOR FARM ROAD 3RD FLOOR CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6095104718 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 form4.xml FORM 4 X0306 4 2021-02-25 0001781983 Aprea Therapeutics, Inc. APRE 0001608536 Coiante Scott M 535 BOYLSTON STREET BOSTON MA 02116 true SVP, Chief Financial Officer Common Stock 2021-02-25 4 A 0 33000 0 A 35500 D Common Stock 2021-02-25 4 A 0 63500 0 A 99000 D Stock Option (right to Buy) 6 2021-02-25 4 A 0 143000 0 A 2031-02-25 Common Stock 143000 143000 D These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 21,166 shares on August 25, 2021, (ii) 21,167 shares on February 25, 2022 and (iii) 21,167 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. /s/ Scott M. Coiante 2021-03-01